查看購物車
  • Simplified Chinese
  • English
2021-2031年北美治療性疫苗市場報告：範圍、細分、動態和競爭分析
市場調查報告書
商品編碼
1871433

2021-2031年北美治療性疫苗市場報告：範圍、細分、動態和競爭分析

North America Therapeutic Vaccines Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 121 Pages | 訂單完成後即時交付

價格

預計北美治療性疫苗市場將大幅成長，到 2031 年將達到約 1,360,744.52 千美元，高於 2024 年的 565,764.46 千美元，2024 年至 2031 年的年複合成長率(CAGR) 為 13.4%。

執行摘要和市場分析

北美治療性疫苗市場主要分為三大區域：美國、加拿大和墨西哥。由於癌症發病率上升、研發投入增加以及新產品上市數量顯著成長等因素，美國預計將成為市場成長的主要驅動力。此外，新產品上市、獲得監管部門批准、建立合作夥伴關係和進行收購等策略措施也進一步推動了該地區治療性疫苗市場的成長。

市場區隔分析

治療性疫苗市場可以透過產品類型、技術和最終用戶等多個細分市場進行分析。

  • 按產品分類：市場分為癌症疫苗、傳染病疫苗和其他疫苗，其中癌症疫苗在 2024 年將佔據最大的市場佔有率。
  • 按技術分類：市場分為同種異體疫苗和自體疫苗，預計到 2024 年，同種異體疫苗將佔據市場佔有率的主導地位。
  • 按最終用戶分類：最終用戶包括醫院、診所等，其中醫院在 2024 年將佔最大佔有率。

市場展望

受人口老化、生活方式改變和環境影響等因素驅動，癌症、神經系統疾病和自體免疫疾病等慢性病在全球的發生率呈上升趨勢。世界衛生組織（世衛組織）的數據顯示，非傳染性疾病每年導致4,100萬人死亡，佔總死亡人數的74%。 2022年，全球新增癌症病例約2,000萬例，約970萬人死於癌症。此外，2024年4月發表在《柳葉刀神經病學》雜誌上的一項研究表明，截至2021年，全球有超過30億人（佔全球人口的43%）患有神經系統疾病。自體免疫疾病影響已開發國家5%至10%的人口，約有5,000萬美國人受到影響。世衛組織也報告稱，截至2023年8月，全球有超過180萬人患有多發性硬化症。

這些令人震驚的統計數據凸顯了開發創新療法的迫切需求。治療性疫苗旨在治療現有疾病而非預防疾病，目標是激活免疫系統以對抗特定疾病。例如，Sipuleucel-T（Provenge）疫苗已顯示出提高前列腺癌患者存活率的潛力。隨著對慢性病創新療法的需求不斷成長，治療性疫苗有望為疾病的長期管理和改善患者預後提供新的途徑。

國家概況

北美治療性疫苗市場主要由美國、加拿大和墨西哥組成，其中美國在2024年將佔據最大的市場佔有率。美國治療性疫苗市場的成長主要受慢性疾病（包括癌症和傳染病）日益普遍的推動。美國癌症協會報告稱，2022年美國新增癌症病例超過190萬例，導致約61萬人死亡。預計到2024年，美國癌症確診病例將達200萬例。癌症病例的激增推動了對創新治療方案的需求，而治療性疫苗為傳統療法提供了極具前景的替代方案。 Provenge是首個獲得FDA批准的前列腺癌治療性疫苗，它充分展現了免疫療法延長患者存活期的潛力。癌症發生率的上升促使人們加大研發投入，並促進企業與學術機構之間的合作。

公司簡介

治療性疫苗市場的主要參與者包括CureVac SE、THERAVECTYS SA、Transgene SA、INOVIO Pharmaceuticals Inc、ISA Pharmaceuticals BV、Amgen Inc、Merck & Co Inc、印度血清研究所、BioNTech SE和Dendreon等。這些公司正採取多種策略，包括擴張、產品創新以及併購，以增強其產品組合併擴大市場佔有率。

目錄

第1章：引言

第2章：執行概要

  • 關鍵見解

第3章：研究方法

  • 二手研究
  • 初步研究
    • 假設的提出：
    • 宏觀經濟因素分析：
    • 發展基數：
    • 數據三角測量：
    • 國家層面資料：

第4章：北美治療性疫苗市場－主要市場動態

  • 市場促進因素
    • 慢性病盛行率上升
    • 增加疫苗研發的投資與資金投入
  • 市場限制
    • 監管挑戰
  • 市場機遇
    • 拓展產品線
  • 未來趨勢
    • 疫苗技術的進步
  • 駕駛員和安全帶的影響：

第5章：治療性疫苗市場－北美市場分析

  • 2021-2031年北美治療性疫苗市場收入
  • 北美治療性疫苗市場預測分析

第6章：北美治療性疫苗市場分析－依產品分類

  • 癌症疫苗
  • 傳染病疫苗
  • 其他

第7章：北美治療性疫苗市場分析－依技術分類

  • 同種異體疫苗
  • 自體疫苗

第8章：北美治療性疫苗市場分析－以最終用戶分類

  • 醫院
  • 診所
  • 其他

第9章：北美治療性疫苗市場—國別分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

第10章：治療性疫苗市場－產業概況

  • 概述
  • 治療性疫苗市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第11章：公司簡介

  • Dendreon
  • BioNTech SE
  • Serum Institute of India Pvt. Ltd
  • Merck & Co Inc
  • Amgen Inc
  • ISA Pharmaceuticals BV
  • INOVIO Pharmaceuticals Inc
  • Transgene SA
  • THERAVECTYS SA
  • CureVac SE

第12章：附錄

Product Code: BMIRE00032090

The North America therapeutic vaccines market is projected to grow significantly, reaching approximately USD 1,360,744.52 thousand by 2031, up from USD 565,764.46 thousand in 2024, reflecting a compound annual growth rate (CAGR) of 13.4% from 2024 to 2031.

Executive Summary and Market Analysis

The therapeutic vaccines market in North America is divided into three main regions: the United States, Canada, and Mexico. The U.S. is expected to be a key driver of market growth due to several factors, including the rising incidence of cancer, increased investment in research and development, and a notable rise in product launches. Additionally, strategic initiatives such as the introduction of new products, regulatory approvals, partnerships, and acquisitions are further enhancing the growth of the therapeutic vaccine market in this region.

Market Segmentation Analysis

The therapeutic vaccines market can be analyzed through various segments, including product type, technology, and end user.

  • By Product: The market is categorized into cancer vaccines, infectious disease vaccines, and others, with cancer vaccines holding the largest market share in 2024.
  • By Technology: The market is divided into allogenic and autologous vaccines, where allogenic vaccines are expected to dominate the market share in 2024.
  • By End User: The end-user segment includes hospitals, clinics, and others, with hospitals accounting for the largest share in 2024.

Market Outlook

The prevalence of chronic conditions such as cancer, neurological disorders, and autoimmune diseases is on the rise globally, driven by factors like aging populations, lifestyle changes, and environmental influences. According to the World Health Organization (WHO), noncommunicable diseases lead to 41 million deaths annually, representing 74% of total mortality. In 2022, around 20 million new cancer cases were diagnosed, with approximately 9.7 million deaths attributed to the disease. Furthermore, a study published in The Lancet Neurology in April 2024 indicated that over 3 billion people, or 43% of the global population, were living with neurological conditions as of 2021. Autoimmune diseases affect 5-10% of the population in industrialized nations, impacting around 50 million Americans. The WHO also reported that over 1.8 million people worldwide suffered from multiple sclerosis as of August 2023.

These alarming statistics underscore the urgent need for innovative therapeutic solutions. Therapeutic vaccines are designed to treat existing diseases rather than prevent them, aiming to activate the immune system to target specific diseases. For instance, the Sipuleucel-T (Provenge) vaccine has shown promise in improving survival rates for prostate cancer patients. As the demand for innovative treatments for chronic diseases rises, therapeutic vaccines are positioned to provide new avenues for long-term disease management and enhanced patient outcomes.

Country Insights

The North American therapeutic vaccines market is primarily composed of the U.S., Canada, and Mexico, with the U.S. holding the largest market share in 2024. The growth of the therapeutic vaccines market in the U.S. is fueled by the increasing prevalence of chronic diseases, including cancer and infectious diseases. The American Cancer Society reported that in 2022, over 1.9 million new cancer cases were diagnosed, resulting in approximately 610,000 deaths. In 2024, the number of cancer diagnoses in the U.S. is expected to reach 2 million. This surge in cancer cases is driving the demand for innovative treatment options, with therapeutic vaccines offering promising alternatives to traditional therapies. Provenge, the first FDA-approved therapeutic cancer vaccine for prostate cancer, exemplifies the potential of immunotherapies to extend patient survival. The rising incidence of cancer is prompting increased investment in research and development and fostering collaborations between companies and academic institutions.

Company Profiles

Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon, among others. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their product offerings and increase their market presence.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. North America Therapeutic Vaccines Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Prevalence of Chronic Conditions
    • 4.1.2 Increasing Investments and Funding for Vaccine Development
  • 4.2 Market Restraints
    • 4.2.1 Regulatory Challenges
  • 4.3 Market Opportunities
    • 4.3.1 Extending Product Pipeline
  • 4.4 Future Trends
    • 4.4.1 Advancements in Vaccine Technology
  • 4.5 Impact of Drivers and Restraints:

5. Therapeutic Vaccines Market - North America Market Analysis

  • 5.1 North America Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • 5.2 North America Therapeutic Vaccines Market Forecast Analysis

6. North America Therapeutic Vaccines Market Analysis - by Product

  • 6.1 Cancer Vaccine
    • 6.1.1 Overview
    • 6.1.2 Cancer Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 6.2 Infectious Disease Vaccine
    • 6.2.1 Overview
    • 6.2.2 infectious Disease Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 6.3 Others
    • 6.3.1 Overview
    • 6.3.2 Others: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

7. North America Therapeutic Vaccines Market Analysis - by Technology

  • 7.1 Allogenic Vaccine
    • 7.1.1 Overview
    • 7.1.2 Allogenic Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 7.2 Autologous Vaccine
    • 7.2.1 Overview
    • 7.2.2 Autologous Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

8. North America Therapeutic Vaccines Market Analysis - by End User

  • 8.1 Hospitals
    • 8.1.1 Overview
    • 8.1.2 Hospitals: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 8.2 Clinics
    • 8.2.1 Overview
    • 8.2.2 Clinics: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

9. North America Therapeutic Vaccines Market - Country Analysis

  • 9.1 North America
    • 9.1.1 North America Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.1 North America Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.2 United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.2.1 United States: North America Therapeutic Vaccines Market Share - by Product
        • 9.1.1.2.2 United States: North America Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.2.3 United States: North America Therapeutic Vaccines Market Share - by End User
      • 9.1.1.3 Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.3.1 Canada: North America Therapeutic Vaccines Market Share - by Product
        • 9.1.1.3.2 Canada: North America Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.3.3 Canada: North America Therapeutic Vaccines Market Share - by End User
      • 9.1.1.4 Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.4.1 Mexico: North America Therapeutic Vaccines Market Share - by Product
        • 9.1.1.4.2 Mexico: North America Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.4.3 Mexico: North America Therapeutic Vaccines Market Share - by End User

10. Therapeutic Vaccines Market - Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in the Therapeutic Vaccines Market
  • 10.3 Organic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Inorganic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Dendreon
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 BioNTech SE
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Serum Institute of India Pvt. Ltd
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Merck & Co Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Amgen Inc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 ISA Pharmaceuticals BV
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 INOVIO Pharmaceuticals Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Transgene SA
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 THERAVECTYS SA
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 CureVac SE
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. North America Therapeutic Vaccines Market Segmentation
  • Table 2. North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Table 3. North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Product
  • Table 4. North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Technology
  • Table 5. North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by End User
  • Table 6. North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Country
  • Table 7. United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 8. United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 9. United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 10. Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 11. Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 12. Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 13. Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 14. Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 15. Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 16. Recent Organic Growth Strategies in the Therapeutic Vaccines Market
  • Table 17. Recent Inorganic Growth Strategies in the Therapeutic Vaccines Market
  • Table 18. Glossary of Terms, Therapeutic Vaccines Market

List Of Figures

  • Figure 1. North America Therapeutic Vaccines Market Segmentation - Country
  • Figure 2. North America Therapeutic Vaccines Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. North America Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • Figure 5. North America Therapeutic Vaccines Market Share (%) - by Product (2024 and 2031)
  • Figure 6. Cancer Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 7. infectious Disease Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 8. Others: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 9. North America Therapeutic Vaccines Market Share (%) - by Technology (2024 and 2031)
  • Figure 10. Allogenic Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 11. Autologous Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 12. North America Therapeutic Vaccines Market Share (%) - by End User (2024 and 2031)
  • Figure 13. Hospitals: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 14. Clinics: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 15. Others: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 16. North America Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 17. United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 18. Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 19. Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 20. Growth Strategies in the Therapeutic Vaccines Market